EN101

a 20-mer oligonucleotide that is chemically modified by the insertion of 2'-oxymethyl groups at the three terminal positions of the 3' end; selectively lowers AChE-R in blood and muscle yet leaves unaffected the synaptic variant AChE-S

Also Known As:

Networked: 5 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Soreq, Hermona: 3 articles (12/2012 - 10/2006)
2.	Argov, Zohar: 2 articles (12/2012 - 01/2008)
3.	Brenner, Talma: 2 articles (05/2006 - 04/2006)
4.	Hamra-Amitay, Yasmine: 2 articles (05/2006 - 04/2006)
5.	Apolski, Slobodan: 1 article (12/2012)
6.	Milic-Rasic, Vedrana: 1 article (12/2012)
7.	Sussman, Jon: 1 article (12/2012)
8.	Wirguin, Yitzhak: 1 article (12/2012)
9.	Brawer, Solli: 1 article (01/2008)
10.	Hazum, Eli: 1 article (01/2008)

Related Diseases

1.	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 05/01/2006 - "Using stimulated-single fiber electromyography, we show that EN101 treatment of rats with experimental autoimmune myasthenia gravis (EAMG), improved the mean consecutive difference (MCD) and blocking for 24h. " 10/01/2006 - "In rats with experimental autoimmune myasthenia gravis, oral delivery of Monarsen improved muscle action potential in a lower dose regimen (nanomolar versus micromolar), rapid and prolonged manner (up to 72 h versus 2-4 h) as compared with the currently used small molecule anticholinesterases. "
2.	Myasthenia Gravis 12/01/2012 - "Preliminary results of a double-blinded phase II cross-over study compared 10, 20, and 40 mg EN101 administered to patients with myasthenia gravis. " 01/01/2008 - "Antisense treatment for myasthenia gravis: experience with monarsen." 01/01/2008 - "Sixteen patients with seropositive myasthenia gravis who were responsive to pyridostigmine were withdrawn from it and treated with Monarsen. "
3.	Inflammation (Inflammations) 04/01/2006 - "Treatment of the central nervous system (CNS) inflammatory disease, experimental autoimmune encephalomyelitis (EAE), with EN101, an anti-sense oligodeoxynucleotide, targeted to AChE mRNA, reduced the clinical severity of the disease and CNS inflammation intensity. "
4.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 04/01/2006 - "Treatment of the central nervous system (CNS) inflammatory disease, experimental autoimmune encephalomyelitis (EAE), with EN101, an anti-sense oligodeoxynucleotide, targeted to AChE mRNA, reduced the clinical severity of the disease and CNS inflammation intensity. "

Related Drugs and Biologics

1.	Cholinesterase Inhibitors (Anticholinesterases)
2.	Messenger RNA (mRNA)
3.	Pyridostigmine Bromide (Pyridostigmine)
4.	Oligodeoxyribonucleotides